Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979336 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
A Phase 2 study of Ulcerative Colitis, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
- 20
- Study locations
NCT06979336: Recruiting Phase 2 study of Ulcerative Colitis, sponsored by Genentech.
NCT06979336 is a Phase 2 study of Ulcerative Colitis that is actively recruiting participants, run by Genentech. The registered enrollment target is 224 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06979336, a Phase 2 study of Ulcerative Colitis, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
Primary Outcome
Clinical remission is defined as the Modified Mayo Score (mMS) of ≤ 2, including stool frequency subscore of ≤ 1, rectal bleeding subscore of 0, and endoscopy subscore of ≤ 1.
Conditions Studied
Interventions
- DRUG RO7837195
- DRUG RO7837195 Matched Placebo
Study Locations (20)
Other
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University - Hangzhou
- PreventaMed, s.r.o. - Olomouc
- Nemocnice Slany - Slaný
California
- Gastro Care Institute - Lancaster
- Medical Associates Research Group, Inc. - San Diego
Lombardy
- Fondazione Poliambulanza Istituto Ospedaliero - Brescia
- ASST Rhodense, Rho Memorial Hospital - Rho
Colorado
- Peak Gastroenterology Associates - Colorado Springs
Florida
- Clinical Research of Osceola, LLC - Kissimmee
New York
- Intercity Gastroenterology - Fresh Meadows
North Carolina
- Monroe Biomedical Research - Monroe
Paraná
- Centro Digestivo de Curitiba - Curitiba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 2 |
What NCT06979336 shows while recruiting
NCT06979336 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which RO7837195 is the first listed.
NCT06979336 names 20 study sites across 16 states, led by Other, California, Lombardy.
Frequently Asked Questions
What is clinical trial NCT06979336 about?
NCT06979336 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)". The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
What is the current status of trial NCT06979336?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2025-09-29. Estimated completion is 2028-10-31.
What conditions does trial NCT06979336 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT06979336?
The interventions under investigation include: RO7837195 (DRUG), RO7837195 Matched Placebo (DRUG).
Who is sponsoring clinical trial NCT06979336?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06979336 being conducted?
This trial has 20 study locations across California, Colorado, Florida, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06979336's enrollment target sits among peer trials
224 41st of 122 higher than 82 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI